Skip to main content
. 2021 Apr 15;131(8):e135963. doi: 10.1172/JCI135963

Figure 4. Administration of CI-976 in vitro and in vivo.

Figure 4

(A–D) C2C12 myoblasts were differentiated into myotubes with either CI-976 or vehicle. (A and B) Quantification of MC540 fluorescence (n = 6). (C and D) Western blot and quantification of Thr308 phosphorylation and total Akt in the presence (12 nM) and absence of insulin (n = 14; P = 0.024, main effect of insulin). (E–G) WT C57BL6/J mice were fed with HFD for 6 weeks, with subcutaneous injection for the last 7 days with vehicle (1:9 ethanol/polyethylene glycol) or 30 mg/kg CI-976. Body mass (E), intraperitoneal glucose tolerance excursion curves (F), and AUC (G) from glucose tolerance tests on vehicle-treated or CI-976–injected mice (n = 8 per group). Two-tailed t tests (B, E, and G) or 2-way ANOVA with Šidák’s multiple-comparison test (D and F) was performed. All data are represented as mean ± SEM. *P ≤ 0.05.